Clinical Trial Update: A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating Setanaxib co-administered with Pembrolizumab in recurrent or metastatic head and neck squamou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Setanaxib (GKT137831)

Snippet

Sponsor: Calliditas Therapeutics Suisse SA | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2025-05-09